More articles from 05.01 - Airway pharmacology and treatment

Risk factors and guideline adherence of empiric antibiotic use in community-acquired pneumonia
S Pascual Guardia, J Marin-Corral, F Amati, S Aliberti, M Carugati, O Sibila, F Sanz, A Rodriguez, G Sotgiu, P J Marcos, M I Restrepo

European Respiratory Journal Sep 2022, 60 (suppl 66) 4255; DOI: 10.1183/13993003.congress-2022.4255
Real-world effectiveness (RWE) of dupilumab in reducing healthcare resource utilization among moderate-to-severe asthma patients
A Pawar, M S Blaiss, B D Modena, A H Khan, L De Prado Gómez, Y Zhang, S Siddiqui, J A Jacob-Nara, L De Prado Gomez

European Respiratory Journal Sep 2022, 60 (suppl 66) 4185; DOI: 10.1183/13993003.congress-2022.4185
Asthma exacerbation rate reduction with benralizumab in an integrated analysis of the real-world XALOC-1 study
D J Jackson, G Pelaia, A Padilla-Galo, M Watt, S Kayaniyil, S Boarino, J S Tena, V H Shih, T N Tran, D Arbetter, D Cohen, R Katial, J Kwiatek, A Shavit, B Emmanuel, P Nair

European Respiratory Journal Sep 2022, 60 (suppl 66) 4592; DOI: 10.1183/13993003.congress-2022.4592
Evaluating multiple eosinophil measurements when stepping up to ICS/LAMA/LABA triple therapy in patients with COPD: a post-hoc analysis of ETHOS
D Singh, M Bafadhel, J R Hurst, P Darken, M Patel

European Respiratory Journal Sep 2022, 60 (suppl 66) 4346; DOI: 10.1183/13993003.congress-2022.4346
Understanding how azithromycin reduces asthma exacerbations and the underlying mechanisms of macrolides
L Jurak, I Yang, M Hill, J Simpson, J Upham

European Respiratory Journal Sep 2022, 60 (suppl 66) 4372; DOI: 10.1183/13993003.congress-2022.4372
Biologic therapies could prevent lung function decline in severe asthma: a 3 years real life observational study
N Bougard, F Schleich, S Graff, A Frix, V Paulus, F Guissard, R Louis

European Respiratory Journal Sep 2022, 60 (suppl 66) 4179; DOI: 10.1183/13993003.congress-2022.4179
KCa3.1 inhibition possesses complex anti-asthmatic effect in a guinea pig model of chronic asthma
M Šutovská, J Mažerik, S Fraňová

European Respiratory Journal Sep 2022, 60 (suppl 66) 4632; DOI: 10.1183/13993003.congress-2022.4632
Early response and remission with benralizumab in patients with severe asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP) in the prospective real-world ImPROve Asthma study
S Korn, H Watz, B Emmanuel, T Plate, M Saathoff, A Shavit, T Grund, M Lommatzsch

European Respiratory Journal Sep 2022, 60 (suppl 66) 4620; DOI: 10.1183/13993003.congress-2022.4620
Identification and characterisation of selective antagonists for TMEM16A(acd) isoform for the treatment of obstructive respiratory diseases
P P saintot, C Carignani, J Phillips, C Virginio

European Respiratory Journal Sep 2022, 60 (suppl 66) 4414; DOI: 10.1183/13993003.congress-2022.4414
International, prospective study of mepolizumab in severe asthma: REALITI-A at 2yrs
C Caruso, G W Canonica, M Patel, A Smith, M C Liu, R Alfonso-Cristancho, R G Price, R W Jakes, L Demetriou, A Valero, C Pilette, P Howarth

European Respiratory Journal Sep 2022, 60 (suppl 66) 4589; DOI: 10.1183/13993003.congress-2022.4589

Main menu

User menu

Search

More articles from 05.01 - Airway pharmacology and treatment

Pages

Contact us